These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30136248)

  • 21. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving siRNA bio-distribution and minimizing side effects.
    Scaggiante B; Dapas B; Farra R; Grassi M; Pozzato G; Giansante C; Fiotti N; Grassi G
    Curr Drug Metab; 2011 Jan; 12(1):11-23. PubMed ID: 21222588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside.
    Zatsepin TS; Kotelevtsev YV; Koteliansky V
    Int J Nanomedicine; 2016; 11():3077-86. PubMed ID: 27462152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Innovations in siRNA research: a technology comes of age.
    Hefferon KL
    Recent Pat Antiinfect Drug Discov; 2010 Nov; 5(3):226-39. PubMed ID: 20812899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical advances of siRNA therapeutics.
    Hu B; Weng Y; Xia XH; Liang XJ; Huang Y
    J Gene Med; 2019 Jul; 21(7):e3097. PubMed ID: 31069898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
    De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
    J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic pharmacology: progresses in siRNA delivery and therapeutic applications.
    Scherman D; Rousseau A; Bigey P; Escriou V
    Gene Ther; 2017 Mar; 24(3):151-156. PubMed ID: 28121307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small-interfering RNA (siRNA)-based functional micro- and nanostructures for efficient and selective gene silencing.
    Lee SH; Chung BH; Park TG; Nam YS; Mok H
    Acc Chem Res; 2012 Jul; 45(7):1014-25. PubMed ID: 22413937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. siRNA: novel therapeutics from functional genomics.
    Joshi BH; Pachchigar KP
    Biotechnol Genet Eng Rev; 2014 Oct; 30(1-2):1-30. PubMed ID: 25023460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid Nanoparticle Systems for Enabling Gene Therapies.
    Cullis PR; Hope MJ
    Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular delivery in vivo of siRNA-based therapeutics.
    Aigner A
    Curr Pharm Des; 2008; 14(34):3603-19. PubMed ID: 19075737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chitosan-based siRNA delivery systems.
    Ragelle H; Vandermeulen G; Préat V
    J Control Release; 2013 Nov; 172(1):207-218. PubMed ID: 23965281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
    Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
    J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short interfering RNA (siRNA): tool or therapeutic?
    Cejka D; Losert D; Wacheck V
    Clin Sci (Lond); 2006 Jan; 110(1):47-58. PubMed ID: 16336204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo cellular delivery of siRNA.
    Brink PR; Robinson RB; Rosen MR; Cohen IS
    IDrugs; 2010 Jun; 13(6):383-7. PubMed ID: 20506060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics.
    Ranjbar S; Zhong XB; Manautou J; Lu X
    Adv Drug Deliv Rev; 2023 Oct; 201():115052. PubMed ID: 37567502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery.
    Guo J; Fisher KA; Darcy R; Cryan JF; O'Driscoll C
    Mol Biosyst; 2010 Jul; 6(7):1143-61. PubMed ID: 20431817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Supramolecular assemblies in functional siRNA delivery: where do we stand?
    Aliabadi HM; Landry B; Sun C; Tang T; Uludağ H
    Biomaterials; 2012 Mar; 33(8):2546-69. PubMed ID: 22209641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent patents in antiviral siRNAs.
    Saravolac EG; Wong JP; Cairns MJ
    Recent Pat Antiinfect Drug Discov; 2010 Jan; 5(1):44-57. PubMed ID: 19807677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.
    Zimmermann TS; Karsten V; Chan A; Chiesa J; Boyce M; Bettencourt BR; Hutabarat R; Nochur S; Vaishnaw A; Gollob J
    Mol Ther; 2017 Jan; 25(1):71-78. PubMed ID: 28129130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.